To elucidate the role of SF3B4 in hepatocellular carcinoma (HCC) progression and its interaction with SREBF1, highlighting its potential as a therapeutic target.
Key Findings:
SF3B4 expression is significantly elevated in HCC tissues and correlates with poor overall survival (OS) and disease-free survival (DFS), indicating its potential as a prognostic marker.
SF3B4 knockdown leads to widespread transcriptional remodeling and alternative splicing changes, suggesting its role in HCC progression.
SF3B4 directly binds to the 3′UTR of SREBF1 mRNA, enhancing its stability and expression, which may contribute to tumorigenesis.
SREBF1 promotes HCC cell proliferation, invasion, and migration while inhibiting apoptosis, highlighting its oncogenic role.
Overexpression of SREBF1 partially rescues malignant phenotypes induced by SF3B4 knockdown, indicating a critical interaction.
Interpretation:
The SF3B4-SREBF1 axis connects RNA metabolism dysregulation to lipid metabolic reprogramming in HCC, suggesting potential therapeutic targets that could be explored in future studies.
Limitations:
The study primarily focuses on in vitro and xenograft models, which may not fully replicate human HCC complexity, such as tumor microenvironment interactions.
Further clinical studies are needed to validate the findings and explore therapeutic implications in diverse patient populations.
Conclusion:
SF3B4 promotes HCC progression by stabilizing SREBF1 mRNA, providing insights into the molecular mechanisms of HCC and potential therapeutic strategies.
